Trials / Completed
CompletedNCT00111462
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effect of darbepoetin alfa administered in a weight based versus fixed dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darbepoetin alfa |
Timeline
- First posted
- 2005-05-23
- Last updated
- 2013-05-08
Source: ClinicalTrials.gov record NCT00111462. Inclusion in this directory is not an endorsement.